1Lilly and Innovent announce global expansion of TYVYT licensing agreement. Press release. Eli Lilly and Company; August 18, 2020. Accessed April 12, 2021. http://lilly.mediaroom.com/2020-08-18-Lilly-and-Innovent-Announce-Global-Expansion-of-TYVYT-Licensing-Agreement
2Data on file, Innovent Biologics (Suzhou) Co., Ltd.
3Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443-1451. https://doi.org/10.1080/19420862.2019.1654303
4Xu JM, Jia R, Wang Y, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. J Clin Oncol. 2018;36(15 suppl):e15125. American Society of Clinical Oncology abstract. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e15125
5Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12-e19. https://doi.org/10.1016/S2352-3026(18)30192-3